Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Public ClinicalTrials.gov record NCT05254990. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomized, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary objective: \- To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28. Key secondary objectives: * To compare the efficacy of reparixin vs placebo in all-cause mortality at day 180. * To compare the efficacy of reparixin vs placebo in proportion of patients alive and discharged at day 28 * To compare the efficacy of reparixin vs placebo in ventilatory-free days at day 28. * To compare the efficacy of reparixin vs placebo in proportion of patients with IMV (or ECMO) by day 28. * To compare the efficacy of reparixin vs placebo in length of primary hospital stay. Other efficacy objectives \- To compare the efficacy of reparixin vs placebo on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: \- To evaluate safety and tolerability of oral reparixin versus placebo in the specific clinical setting.
Study identification
- NCT ID
- NCT05254990
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 414 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2022 (Actual)
- Primary completion
- Jul 29, 2024 (Actual)
- Completion
- Sep 27, 2024 (Actual)
- Last update posted
- Feb 24, 2026
2022 – 2024
United States locations
- U.S. sites
- 28
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MD Banner University Medical Center /Arizona University | Tucson | Arizona | 85719 | — |
| UCI Health | Orange | California | 92868 | — |
| Denver Health | Denver | Colorado | 80204 | — |
| MedStar Health Research Institute-Hyatteville, Maryland | Washington D.C. | District of Columbia | 20010 | — |
| Research Alliance Inc. | Clearwater | Florida | 33756 | — |
| University of Florida-Jacksonville | Jacksonville | Florida | 32209 | — |
| Emory Johns Creek Hospital | Atlanta | Georgia | 30342 | — |
| Augusta University Health - Augusta University Medical Center | Augusta | Georgia | 30912 | — |
| Northwestern University, Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Methodist Hospital | Gary | Indiana | 46404 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Newton-Wellesley Hospital | Newton | Massachusetts | 02462 | — |
| MidMichigan Medical Center - Midland | Midland | Michigan | 48670 | — |
| William Beaumont Hospital | Royal Oak | Michigan | 48073 | — |
| University Hospital - MU Healthcare | Columbia | Missouri | 65212 | — |
| Washington University, School of Medicine | St Louis | Missouri | 63110 | — |
| Mercy Research St Louis | St Louis | Missouri | 63141 | — |
| NYU Langone Hospital-Brooklyn | Brooklyn | New York | 11220 | — |
| New York University Langone Health | New York | New York | 10016 | — |
| Duke University Hospital | Durham | North Carolina | 27708 | — |
| Oregon Health & Science University (OHSU) - Pulmonary Clinic | Portland | Oregon | 97239 | — |
| Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Baptist Hospitals of Southeast Texas | Beaumont | Texas | 77701 | — |
| Texoma Medical Center | Denison | Texas | 75020 | — |
| University of Utah Hospitals & Clinics | Salt Lake City | Utah | 84108 | — |
| University of Virginia Medical Center | Charlottesville | Virginia | 22903 | — |
| Virginia Commonwealth University Health | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05254990, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05254990 live on ClinicalTrials.gov.